Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Embecta Corp. EMBCV
$33.33
На 18:05, 12 мая 2023
+8.01%
Потенциал через год
Ключевые показатели
-
Marketcap
1908915756.00000000
-
week52high
49.00
-
week52low
27.20
-
Revenue
1165000000
-
P/E TTM
5
-
Beta
0.00000000
-
EPS
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мая 2023 г. в 08:31
Описание компании
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
embecta to Report Fiscal First Quarter 2023 Financial Results
GlobeNewsWire
24 янв 2023 г. в 17:00
PARSIPPANY, N.J., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal first quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, February 14, 2023.
Why Embecta Stock Is Sinking Today
The Motley Fool
20 дек 2022 г. в 11:34
Investors didn't like the diabetes care provider's Q4 update.
embecta to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results
GlobeNewsWire
03 ноя 2022 г. в 17:00
PARSIPPANY, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal fourth quarter and full year 2022 financial results, and provide an operational update, including preliminary fiscal year 2023 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, December 20, 2022.
embecta to Participate in Upcoming Investor Conferences in September
GlobeNewsWire
18 авг 2022 г. в 17:00
PARSIPPANY, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in the following upcoming investor conferences:
embecta Announces Earnings Conference Call Information for the Third Quarter of Fiscal Year 2022
GlobeNewsWire
05 июл 2022 г. в 17:00
PARSIPPANY, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that it will report its financial results for the third quarter of fiscal year 2022 before the market opens on Monday, August 15, 2022.